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SPIN TRAPPING PHARMACEUTICAL
COMPOSITIONS AND METHODS FOR USE
THEREOF

of cells, a Widening of lateral ventricles and de?cits in short
term memory. The precise mechanisms of functional
changes as a result of aging, or other diseases associated

With aging, have not generally been agreed upon, including
several mechanisms for the generation of oxidiZed material
in the brain. A marked reduction in certain neurotransmitter
receptor systems has been associated With increased oxida
tion of proteins. For example, decreases in muscarinic
receptors and other cholinergic systems have been charac

This application is a continuation-in-part of Ser. No.
07/716,952, ?led Jun. 18, 1991 and abandoned on Apr. 26,
1993 and a continuation of Ser. No. 08/167,900, ?led Jul. 29,
1994, (Which Was abandoned on Dec. 2, 1997) Which is a

continuation-in-part of Ser. No. 08/212,800, ?led Mar. 15,
1994, now US. Pat. No. 5,622,994, Which is a continuation

10

of Ser. No. 08/052,870, ?led Apr. 26, 1993, Which Was
abandoned on Mar. 22, 1994, Which is a continuation of Ser.

brain proteins. It has also been hypothesiZed that aging is
associated With multiple minor periods of ischemia (multi

No. 07/716,952, ?led Jun. 18, 1991, Which Was abandoned
on Apr. 26, 1993.

infarct conditions or transient ischemia attacks) Which, over
15

BACKGROUND OF THE INVENTION

The demonstration in a variety of systems, both neural
and nonneural, that there is an age related enhancement of

The present invention is a method and compositions

functions and disease conditions arising from oxidative
Oxygenated tissue suffers damage, in many cases perma
nent damage, if it becomes ischemic and is then reperfused.
The brain appears to be highly susceptible to ischemia/
reperfusion injury. Certain areas of the brain, for example,
the hippocampus and spinal cord, are more susceptible than
other regions of the brain. As a result, ischemia/reperfusion
injury to brain may have a multiplicative effect simply

20

25

system. The data presented in US. Ser. No. 07/589,177
abandoned on Apr. 20, 1993 Was the ?rst report of substan
tial investigations in Which alterations in the oxidiZed pro
30

reperfusion damage. The most likely sites for production of
such radicals as the superoxide (0'2) and hydroxyl (OH')
species, and the precursor oxygen species, H2O2 are the
mitochondrial respiratory chain speci?c enZymes and the

sequences catalyZed by cyclooxygenase and lipoxygenase.
to favor a spurt of free-radical formation, resulting in

eral neuropathy and traumatic nerve damage, as Well as
40

of catecholamines, and oxidation of hypoxanthine by xan
thine oxidase. Despite these events occurring during

45

insult.

Although free radical formation has been postulated to be

50

Cell. Bi0l.5, 167—172 (1985). Phenyl butyl nitrone (PBN)
has been used in a number of these in vitro research studies

using spin trapping to look for free radicals, but until
55

proposition that it could be useful in vivo, particularly With
respect to treatment of tissue damage in the central nervous
system. In vivo, the drug must be able to both cross the blood
brain barrier and act in a manner Which reduces tissue

lar hemorrhage and associated vasospasm, spinal cord
trauma, vascular headaches, and neuroanesthesia adjunct.
It is another object of the present invention to provide
spin-trapping compositions, and methods for use thereof,
Which are useful in treating damage in vivo resulting from
peripheral nervous system diseases, including diabetic
peripheral neuropathy and traumatic nerve damage.
It is still another object of the present invention to provide
spin-trapping compositions, and methods for use thereof,
Which are useful in preventing or reversing free radical

60

damage during or folloWing ischemia.
In US. Ser. No. 07/589,177, abandoned on Apr. 20, 1993
the use of PBN and related compounds, as Well as 5,5

dimethyl pyrroline N-oxide (DMPO) and ot-(4-pyridinyl-1
oxide)-N-tert -butylnitrone (POBN), for treatment of aging

bitus ulcers, and ischemic boWel disease.
It is therefore an object of the present invention to provide
spin-trapping compositions and methods for use thereof
Which are useful in preventing or reversing ischemic damage
in vivo, in the CNS, resulting from diseases such as stroke,

aging, Parkinsonism, concussion, Berry aneurysm, ventricu

a likely cause of ischemic damage, it Was dif?cult to directly
demonstrate that such formation occurs and/or that it Was

demonstrated by the data in US. Ser. No. 07/422,651, now
US. Pat. No. 5,025,032 there has been no data to support the

peripheral organ diseases. Examples of peripheral organ
diseases include atherosclerosis, pulmonary ?brosis,

pancreatitis, angioplasty, multiple organ failure, burns, decu

recirculation, When the O2 supply is restored, they represent
metabolic cascades triggered by agonist-receptor

suf?ciently pronounced to overWhelm the antioxidative
defense of the tissue, as revieWed by Curran, et al., M01.

tem (CNS) diseases besides stroke and aging, including
Parkinsonism, trauma, vascular headaches, cerebral palsy,
diabetic neuropathy,and neuroanesthesia adjunct, as Well as
peripheral nervous system diseases such as diabetic periph

HoWever, radicals are also formed during autoxidation of

interactions, energy failure, and/or calcium in?ux during the

tein burden of the central nervous system Was manipulated
and correlated With a functional outcome on the part of the
animal. There are a number of other disorders and diseases
Which have noW been postulated to be associated With

oxidation of proteins, including many central nervous sys
35

many compounds (e.g., catecholamines). Ischemia appears
oxidation of polyenoic free fatty acids, release and reuptake

the level of oxidiZed protein in tissue gives rise to the
possibility that age related dysfunctions in the central ner
vous system may be associated With the build-up of oxidiZed
proteins and oxidiZed macromolecules Within neurons
throughout the central nervous system. The hypothesis is
that cells Which have a buildup of oxidiZed protein are less
functional and less able to maintain the speci?ed role of
those cells in that particular area of the central nervous

because of the necessity for complete integrity of all regions
in order to have proper functioning.
Free radicals have been postulated to be mediators of

a period of time, may give rise to the production of oxidiZed

protein.

containing spin trapping agents for the treatment of dys

damage.

teriZed as they relate to alterations in functions in AlZhe
imers disease. It is noW knoWn that the processes of aging
and AlZheimer’s disease are associated With oxidation of

65

damage in vivo resulting from injury, infection and
in?ammation, especially peripheral organ diseases such as
chronic obstructive pulmonary disease (COPD), atheroscle
rosis (both diabetic and spontaneous), pulmonary ?brosis
due to anti-cancer treatment, drug treatment, pancreatitis,
angioplasty, multi-organ failure folloWing trauma, burns
(chemical, thermal, and radiation), the progressive loss of

Was described. Age related changes in central nervous

myocardial cells leading to cardiac failure as a result of

system function have generally been associated With the loss

age-related oxidation, and ischemic boWel disease.

6,002,001
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It is another object of the present invention to provide
spin-trapping compositions for use in the process of organ

The term alkaryl refers to an alkyl group that has an aryl
substituent.
The term halo (alkyl or alkenyl) refers to an alkyl or
alkenyl group in Which at least one of the hydrogens in the
group has been replaced With a halogen atom. The term

transplantation and preservation.
It is a further object of the present invention to treat
disorders not associated With oxidation, such as undesirable
HDL/LDL ratios, as Well as the treatment of damage arising

haloalkyl speci?cally includes tri?uoromethyl.

from exposure to cytotoxic compounds and radiation.
SUMMARY OF THE INVENTION

Spin trapping compounds in general have noW been
discovered to be effective in treating a variety of disorders,
including disorders such as those arising from ischemia,
infection, in?ammation, exposure to radiation or cytotoxic
compounds, not just of the central and peripheral nervous
systems but of peripheral organ disease having a Wide

10

15

The term nontoxic refers to a compound that has a

compositions that contain spin trapping compounds or phar
20

ECSO/LCSO) of 3 or more.

The spin traps provide a unique signal that can be mea

sured by electron spin spectroscopy (ESR) When it binds to
a free radical. For example, the oxidation of brain tissue
25
involves a free radical intermediate. Brain tissue that has
been treated With PBN has been monitored by ESR. As a free
radical on a lipid or protein is generated, PBN traps the

radical and forms a covalently bound product With the

maceutically acceptable derivatives or salts thereof for use
in medical therapy, for example for the treatment or pro

phylaxis of disorders such as those arising from ischemia,
infection, in?ammation, exposure to radiation or cytotoxic
compounds, not just of the central and peripheral nervous
systems but of peripheral organ disease having a Wide

variety of etiologies.
The invention also includes the use of spin trapping
agents and pharmaceutically acceptable derivatives or salts
thereof in the manufacture of a medicament for treatment or

30

prophylaxis of disorders such as those arising from
ischemia, infection, in?ammation, exposure to radiation or

cytotoxic compounds, not just of the central and peripheral
nervous systems but of peripheral organ disease having a

Wide variety of etiologies.
35

It has noW been discovered that spin-trapping agents are

generally useful in preventing or treating symptoms associ
ated With a very Wide range of disorders of the central and
peripheral nervous system, as Well as peripheral organ

access to the CNS is required for efficacy, that the com

pounds pass through the blood brain barrier.
Many different disorders can be treated using these
compounds, including diseases or disorders of the central
and peripheral nervous systems, and disorders arising from
ischemia, infection, in?ammation, oxidation from exposure

disclosed herein.
The term alkaryl refers to an alkyl group that has an aryl
substituent.

therapeutic index of at least three.
The invention disclosed herein includes pharmaceutical

Spin trapping compounds as referred to herein are mol
ecules that (1) have an unpaired electron; (2) form a stable
compound or complex With a free radical; and (3) are

material, Which has a characteristically unique ESR signal.
The PBN-(lipid or protein) has then been isolated and
identi?ed.
AWide range of spin trapping compounds are disclosed in
detail herein. Other spin traps that meet the above three
requirements are knoWn to those of skill in the art of organic
and medicinal chemistry. An essential criteria for the selec
tion of the spin trap is that it actively trap free radicals
Without cytotoxicity, and that in the applications Where

compound that upon administration to the recipient, is

capable of providing directly or indirectly, the compounds

variety of etiologies.

nontoxic, i.e., have a therapeutic index (margin of safety;

The term aralkyl refers to an aryl group With an alkyl
substituent.
The term pharmaceutically active derivative refers to any

40

disfunction and disease, including not just aging, trauma,
ischemia, but disorders as disparate as undesirable ratios of

lipoproteins, ulcerative colitis, and damage arising from
exposure to radiation and cytotoxic compounds

to radiation or cytotoxic compounds, as Well as due to 45

naturally occurring processes such as aging.

(chemotherapeutic compounds, in most instances).
Useful Spin-Trapping Compounds
PBN and Derivatives thereof.

The preferred spin-trapping compounds are phenyl

DETAILED DESCRIPTION OF THE
INVENTION

N-tert-butylnitrone, also referred to as ot-phenyl t-butyl
nitrone (PBN), and derivatives thereof of the formula:

The term alkyl, as used herein, unless otherWise speci?ed,
refers to a saturated straight, branched, or cyclic hydrocar

H

bon of C1 to C10, and speci?cally includes methyl, ethyl,

/

propyl, isopropyl, cyclopropyl, butyl, isobutyl, t-butyl,
pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl,
cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3
dimethylbutyl, and cyclohexyl.

/O'

x

55

C=N+

\
Y

Wherein:

X is phenyl, imidaZolyl, phenothiaZinyl or

The term alkenyl, as referred to herein, and unless oth

erWise speci?ed, refers to a straight, branched, or cyclic (in
the case of C5_6) hydrocarbon of C2 to C10 With at least one
double bond.
The term aryl, as used herein, and unless otherWise
speci?ed, refers to phenyl or substituted phenyl, Wherein the
substituent is halo or loWer alkyl.
The term halo, as used herein, includes ?uoro, chloro,

bromo, and iodo.
The term aralkyl refers to an aryl group With an alkyl
substituent.

7/752;

\ /

n=1—5, preferably 1—3;
65

R2 =independently (can vary Within the molecule)

halogen, alkyl, oxyalkyl, alkenyl, oxyalkenyl, OH,
NHZ, NHZ, NZ2, NO,

6,002,001
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—SO3H, —OSO3H, SH, —S(alkyl), —S(alkenyl), and
haloalkyl, speci?cally including —CF3;
15

A=O or S; and

Z is a C1 to C6 straight, branched, alkyl or cyclic group;
and
Y is a tert-butyl group that can be hydroXylated or
acetylated at one or more positions; phenyl or

20

25

PBN is the most preferred compound at this time, having
no measurable effect on normal or uninjured cells, although
a number of derivatives are also useful, including hydroXy

derivatives, especially 2-, 3- or 4-hydroXyphenyl t-butyl
nitrone and phenyl (mono-, di- or trihydroXy) tert-butyl

30

nitrone; PBN esters, especially esters Which release 2-, 3-, or
4-hydroXyphenyl t-butyl nitrone such as the acetoXy deriva

tive; 2-, 3-, or 4-carboXyphenyl t-butyl nitrone; phenyl

hydroXybutyl nitrone; alkoXyl derivatives, especially

35

alkoXyl derivatives Which release 2-, 3-, or 4-hydroXyphenyl
t-butyl nitrone, for eXample, the 2-, 3-, or 4- methoXyphenyl
derivatives of PBN; and acetamide derivatives, especially
acetamide derivatives Which release 2-, 3-, or 4- aminophe

nyl t-butyl nitrone; diphenyl nitrone (PPN) and the analo
gous diphenyl nitrone derivatives; N-tert-butyl-(x-(4-nitro
phenyl) nitrone; and N-tert-butyl-ot-(2-sulfophenyl) nitrone.

40

Example of PBN (0t, [3, or y) CYCLODEXTRAN POLY
MER

As used herein, “PBN” refers to both phenyl N-tert-butyl
nitrone and derivatives thereof, unless otherWise stated.
Formulas for PBN and speci?c derivatives thereof are:
cH3
Wherein PBN :

55

connected through one or more hydroXyl moieties of the

cyclodeXtran

6,002,001
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speci?cally including

—CCH3,
or —Z

O—C

CH3

/
20

CH3

N

I

CH3

/

CH3

O

N

|

O

DMPO dimer

wherein R3=independently R2 (that can vary

25
CH 3

CH3

Within the molecule) or H;
and R4 to R9 are independently R2, H or
O—N
30

CH3
CH 3

O

DMPO covalently bound to TEMPO

nR3
Other spin-trapping agents can also be used, such as

CH3

35

5,5-dimethyl pyrroline N-oXide (DMPO), ot-(4-pyridyl

1-oXide)—N-tert-butylnitrone (POBN), 3,3,5,5-tetramethyl-l
pyrroline N-oXide, and 2,4,4,6-tri-tert-butylnitrosobenZene
(BNB), and spin-trapping derivatives thereof. Many com

40

pounds are commercially available or can be synthesiZed
using methods knoWn to those skilled in the art. ot-Phenyl
N-phenylnitrone compounds for use as topical antiin?am
matories are described by U.S. Pat. No. 4,224,340 to

Campbell, et al., the teachings of Which are incorporated

PBN covalently bound to DMPO

POBN and derivatives thereof
45

The general formula for POBN is:

herein.
DMPO and derivatives thereof

The general formula for DMPO, and speci?c derivatives
are:

A

/
B

N+

(L

55

0.

wherein m =0 to 4

TEMPO and derivatives thereof

Wherein A and B are independently —R2, —CHZOH,
—CHZOW, or

60

2,2,6,6-Tetramethyl piperidinooXy (TEMPO) is a nitroX
ide organic free radical trap. The synthesis and chemistry of
nitroXide free radicals is referenced by Galfney, B. J ., pp.

184—238 in Spin Labeling in Pharmacology, Berliner, L. H.,
(Academic Press, NY, NY 976), the teachings of Which are
incorporated herein. TEMPO and several derivatives thereof
65

n is an integer from 1 to 5; and

can be purchased from Aldrich Chemical Co., as can many

other spin traps such as PBN, DMPO, and POBN and some
of their derivatives.

6,002,001
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Conjugates and Polymers of Spin Trapping Compounds

As discussed above, the important criteria for these com

pounds is that they must trap free radicals, especially
hydroxy and superoxide radicals, While remaining non-toxic

In another embodiment, spin trapping compounds are
covalently attached to knoWn pharmaceutical agents, by

methods knoWn to those skilled in the art. Examples of
to normal cells. In those applications Where the compound
must reach the brain and other parts of the CNS, the 5 useful compounds include spin traps covalently bound to
compound must also be loW molecular Weight to pass
antiin?ammatories, neuroactive compounds, antioxidants,
or calcium channel blockers. Examples as illustrated include
through the blood brain barrier. In some applications, the

conjugates of acetaminophen, dopamine (or DOPA), vitamin

higher molecular Weight dimers and polymers of the spin
trap may have advantages.

E, and nifediphene.

CH2— CH2—NH2

HO

DOPAMINE

HO

HO

CH2—(|I—C—OH DOPA
NH2
HO

Derivatives of DOPA

HoCH3
|
|

—
\

R314)“ /

CH —C=N

2

CH

CH3

3

6,002,001
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Other drugs that can be covalently bound to the spin traps

insert a spacer betWeen the spin trap and the biologically

include calcium channel blockers such as nimodipine,

active compound.

nicardipine, nifedipine, nitrendipine, diltriaZam and ?una
raZine; cardiac glycosides such as digitalis and analogues
thereof; adenergic antagonists such as propranalol; metal

Indications that the Compositions are Useful in Treating
The spin trap or free-radical scavenger compositions are
useful in treating a variety of dysfunctions or disorders

chelators such as desferal; modi?ed steroids such as laZ

characteriZed by oxidiZed proteins or lipids in the tissues,

aroids; antiin?ammatories such as prednisone; nonsteroidal
antiin?ammatories such as acetaminophen, ibuprofen, and

cells, or associated ?uids (such as the blood)- Oxidation of
cytosolic protein has been demonstrated to occur in a Wide

indomethacin; antioxidants such as vitamin E; and neuro

variety of pathological conditions.

active compounds such as L-DOPA. The optimal position to

bind the spin trap to the pharmaceutical agent is easily

Accordingly, compounds Which have as their fundamental
mechanism of action the interference of production of

determined using knoWn information on structure activity

oxidiZed protein are useful in the treatment of a Wide variety

relationships and bulk tolerance of the pharmaceutical agent.

of diseases having What appears at ?rst glance to be Widely

In some cases spacers Will be required betWeen the spin-trap

dissimilar etiologies, because the fundamental cause of the

and the conjugated compound in order to preserve maximum

condition is oxidation of protein, nucleic acids, or lipids.

activity.

Disorders are generally divided into disorders of the
central and peripheral nervous system and disorders of the

Spin traps can also be attached to antibodies or ligands for

speci?c receptors (such as certain hormones, enZymes, or

peripheral organs.

even speci?c sugars or carbohydrates) Which are used to

Disorders of the CNS include stroke, aging,
Parkinsonism, concussion, aneurysm, ventricular hemor

“target” or otherWise concentrate the spin trapping com
pound. Depending on the structure of the spin trap, as Well
as the biologically active compound, it may be necessary to

rhage and associated vasospasm, migraine and other vascu

lar headaches, spinal cord trauma, diabetic retinopathy, and

6,002,001
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neuroanesthesia adjunct. Disorders of the peripheral nervous

Concussion
The majority of the research literature indicates that
concussion produces the bulk of its long term effects via

system include diabetic peripheral neuropathy and traumatic
nerve damage.

Peripheral organ disease includes atherosclerosis (both
diabetic and spontaneous), chronic obstructive pulmonary
disease (COPD), pancreatitis, pulmonary ?brosis due to

interruption of brain and spinal cord microcirculation, pro
ducing localiZed ischemia. This interruption in blood How
can be the result of the initial trauma and shearing of
capillaries or the consequence of the brain edema and

chemotherapeutic agents, angioplasty, trauma, burns,
ischemic boWel disease, Wounds, ulcers and bed sores,

lupus, ulcerative colitis, organ transplantation, renal
hypertension, overexertion of skeletal muscle, and epistaxis

(pulmonary bleeding).

compression of the blood vessels. In any event, spin trapping
10

Berry Aneurysm and Other Types of Aneurysm

Other conditions associated With excessive oxidation of
proteins or lipids that can be treated include undesirable or

altered oxidation of loW density lipoprotein, and dysfunction
from exposure to radiation, including x-ray, ultraviolet,
gamma and beta radiation, and cytotoxic compounds,
including those used for chemotherapy for cancer and viral
infections.
Treatment of Central Nervous System Diseases
Stroke
Multiple in vitro studies, as Well as the in vivo data
presented in US. Ser. No. 07/589,177 and US. Ser. No.

compounds are of therapeutic value as they have been
demonstrated to be in models of stroke.

This vascular problem results in bleeding on the brain and
presents as a serious and chronic headache or other neuro
15

20

logic symptom. The condition is ultimately treated by sur
gical repair of the vessel that has developed a Weak Wall.
HoWever, this condition often results in hemorrhage and
neural damage due to the bleeding. In addition, the presence
of blood on the outside of the vessel sensitiZes the vessels to
spasm and increases the risk of a stroke, as is also true in
concussion and other traumatic conditions. In addition to the

radicals generated by spasm and stroke, the iron or other

07/422,651 have demonstrated that there are a series of

metal catalyZed generation of oxygen free radicals, similar

biochemical changes that result in the production of free
radicals folloWing ischemia. PBN and other spin-trapping
compounds can covalently bind to these radicals and prevent
the peroxidation of cellular proteins and fatty acids. The
consequence of the trapping of these carbon-centered and
oxygen-centered radicals is the termination of the propaga
tion phase of free radical production Within the neuron. This
interruption of free radical production can decrease the
mortality and morbidity seen in strokes.

to What has been proposed for ischemia and concussion, also
represents a second source of free radicals.
25

Ventricular Hemorrhage and Associated Vasospasm
The same biochemical and physiological conditions as

described for Berry Aneurysm and their management by
spin trapping compounds Will apply for these conditions.

Aging

Migraine and Other Vascular Headaches
Migraines are thought to arise in part from large vessel
vasodilation and compression of the microcirculation of the
cortex. This is another form of ischemialreperfusion injury.

Aging has been demonstrated to be associated With the

While spin-trapping compounds Will not prevent the initial

30

production of abnormally high levels of oxidiZed proteins.
The consequence of this increased level of protein oxidation
is an abnormally loW level of critical enZymes in the affected
cells. While not all cells have been evaluated, it appears
from the in vivo data presented in US. Ser. No. 07/589,177
and US. Ser. No. 07/422,651, and reports of in vitro studies,
that most, if not all, cells in the body Will undergo abnor

35

occurrence of these vascular headaches, they limit the extent
or frequency by trapping the free radicals that are generated

during the ischemia phase.
Spinal Cord Trauma
Spinal cord trauma involves the interruption of the normal
vascular supply due to shearing forces at the time of the
40

initial trauma and as a result of the subsequent edema of the

mally high levels of protein oxidation. Decreases in anti
oxidant systems and abnormally loW levels of mitochondrial

such trauma Will also generate vasospasm and directly

function have been described. The protein oxidation is

generated oxygen free radicals. Spin trapping compounds

tissue. In addition, the hemorrhage that often accompanies

thought to arise from oxygen free radicals, largely generated
via a metal catalyZed reaction Within the cell. Studies have
noW been conducted that daily administration of a free

limit this process and terminate the intracellular cascade of
45

radical spin trapping compound, PBN, for fourteen days

lipid and protein oxidation.
Neuroanesthesia Adjunct
Several procedures involve resection of brain tissue Which
Will result in hemorrhage in the immediate area. Other

completely reverses this process. Not only is the level of

protein oxidation decreased, but the abnormally loW level of

surgical procedures may be associated With increased risk of

enZyme activity is restored to normal.
Parkinsonism

cerebral blood ?oW interruption, either as a natural conse

quence of the procedure, e.g., cardiac surgery or heart

Research has indicated that one of the principle sources of

transplantation, or due to the unexpected interruption of

dopaminergic damage to the striatum is via free radical

110W, e.g., hemorrhage, clot folloWing angioplasty, cardiac

mediated oxidation. Dopamine can be oxidiZed to the neu

rotoxin 6-OH dopamine Within the neuron. This neurotoxin
is activated by a second oxidation. Both of these reactions

55

arrest during surgery. In all of these conditions, spin
trapping compounds Will limit free radical mediated
damage, and Will limit the development of antigenic reac

production and attack on the dopamine, a naturally occur

tions or other changes in the vascular endothelium that Will
increase the risk of the development of a reaclusive injury.

ring neurotransmitter. These oxygen radical mediated oxi

Reduction in free radical mediated damage limits antigen/

dations are thought to occur at a relatively sloW rate and to 60

antibody mediated tissue damage.
Peripheral Nervous System Diseases

are thought to occur as a result of oxygen free radical

be responsible for the progressive loss of motor function in
Parkinsonism and related conditions. Based upon the dem

Diabetics are Well knoWn for their tendencies to develop

peripheral neuropathies and progressively lose sensation in

onstration that chronic administration of PBN can decrease

the progressive oxidation that occurs folloWing a stroke, it is

believed that PBN and other spin-trapping compounds Will
be effective in limiting the production of the neurotoxic

dopamine oxidation products.
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limbs. In addition, diabetics have a higher risk to develop
atherosclerosis, Which may affect microvascular function.
One of the most frequently seen biochemical consequences

of diabetes is excessive glycation of proteins. It is believed
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that following glycation, there is a burst of protein oxidation
that is mediated by oxygen free radicals. It is thought that
this process of excessive glycation is critical in the devel

Alcoholic pancreatitis is probably due to the direct effects of
the ethanol radical and the indirect vascular effects of
acetaldehyde mediated direct damage to proteins and indi
rect damage via catecholamine release and mitochondrial

opment of damage to neurons and axons in the diabetic.

Since spin trapping compounds are quite effective in limit

metabolism. There is currently no treatment for acute pan

ing intracellular free radical mediated damage, such com
pounds can be used in the chronic management of diabetic
neuropathies and other long term adverse consequences of
diabetes.
Traumatic Nerve Damage
Crushing injury to peripheral nerves, as in the hands,
arms, and legs, involves interruption of blood ?oW

creatitis. If the condition does not abate, it is generally
regarded as fatal in the severe form. Spin-trapping agents
can be used to mediate the acute reaction, alloWing the
patient time to recover.
10

Angioplasty
In the process of re-expanding or laser removal of

atheroma, there are periods of ischemia and reperfusion of

(ischemia) and edema. Effective and prompt repair is depen

the vessel or energy mediated production of free radicals.

dent on the re-establishment of an effective oxygen and

Recent studies have demonstrated that during this period,
superoxide and nitric oxide are produced. These products
have been demonstrated to further damage the endothelium

nutrient supply. Often recovering tissue tends to outgroW its
blood supply and is restricted in recovery by the ischemia

15

that occurs as the tissue outgroWs the vascular supply.

and may also remove or damage the natural relaxant systems

Spin-trapping compounds can be used to provide greater
tolerance of partial hypoxia as vascular supply groWs to
reach the healing tissue. In addition, the same ischemia/
hypoxia protection that occurs in the non-vascular tissue

that locally control the vascular tone. If uncontrolled, such
changes are likely to result in an increased risk of
20

may also enhance the groWth of the endothelia as the
revasculariZation process occurs.

Peripheral Organ Diseases
Atherosclerosis (both diabetic and spontaneous
Diabetic atherosclerosis involves the abnormal and exces

25

sive glycation of protein in the vascular Wall. As discussed
above for diabetic neuropathy, this involves oxygen radical

development in the patient of a negative nitrogen balance,

poor protein synthetic capacity, pulmonary dysfunction, and
abnormal cytokine production. Tumor necrosis factor (TNF)

mal processing of cellular protein and other cellular con
stituents. In vitro studies have been conducted that demon

is excessively elevated during this process. TNF is associ
ated With the cellular generation of oxygen free radicals in

strate that PBN inhibits or reduces oxidation of loW density

tissue and may be one of the primary causes of this condi

tion. The activation of macrophages and lymphocytes also
35

controls, 0.1 mM PBN Was added to test samples, and the
controls and sealed samples incubated at 4° C. for seven
Weeks.
The results are shoWn in Table 1.
TABLE 1
Testing of antioxidation activity of PBN
control +

Test

PBS

(nM/ml)

% inhibition"

NP132 plasma
NP134 plasma
NP135 plasma

0.55
0.18
0.32

0.45
0.14
0.25

18.2
22.2
21.9

NP133 LDL
NP135 LDL

0.54
0.33

0.28
0.11

48.1
66.7

plays a critical role in the condition. Free radical production
by the White cells is part of the process of multiple organ
damage. Spin-trapping compounds can prevent the propa
gation phase of this condition and limit the extent of
cachexia and organ damage folloWing severe trauma.

Diabetic Retinopathy
40

sample

Multi-Organ Failure FolloWing Trauma
A characteristic problem folloWing extreme trauma is the

production and consequent further damage to cytosolic
proteins. Spin-trapping compounds Will prevent this abnor

lipoprotein in plasma. Plasma samples Were tested for oxi
dation of lipid measured using thiobarbioturic acid reactive
substance (TBAR, nM) and % inhibitionbuffered sion calcu
lated. Phosphate buffered saline (PBS) Was added to

re-occlusion of the same vessel. Spin-trapping compounds
can prevent the generation of the oxy-radical cascade and
thereby reduce the likelihood of reocclusion folloWing
angioplasty. In the diabetic, there is also an increased risk of
cutaneous alteration associated With vascular dysfunction
and poor perfusion of the dermis.

45

Diabetes is a disease of abnormal glycation and partial
ischemia. Both conditions promote free radical production.
The relatively common condition of diabetic retinopathy is
thought to involve a microvascular and protein dysfunction
of the retina. Spin-trapping compounds can limit the glyca
tion mediated production of free radicals and the damage

caused by microvascular interruptions.
Burn Treatment and Healing
Healing from serious burns is limited by the inability of

the repairing vascular system to supply the rapidly groWing
50 cutaneum. Periods of ischemia in the dermis Will occur as

the groWing skin cannot be adequately supplied. This
*The actual percent inhibition in the presence of PBN is greater than the
measured value due to interference in the assay by the PBN.

Chronic Obstructive Pulmonary Disease (COPD)
COPD has been demonstrated to involve the attack of

interstitial alveolar macrophages on pulmonary tissue. Ani
mal models of this clinical condition have demonstrated that
increases or decreases in superoxide dismutase activity in
the lung can result in decreases or increases in pulmonary
pathology, respectively. An alternative approach is to pro
vide to the pulmonary tissue, either via the pulmonary
vascular supply or via the airWay, radical spin-trapping

55
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the prognosis is not good. The generation of ischemia
derived oxygen radicals and damage to the intestine is

compounds Which Will limit the peroxidation of pulmonary
tissue and the consequent loss of alveolar tissue.
Pancreatitis
Pancreatitis is believed to be the result of ischemic or

chemically derived peroxidation of pancreatic parenchyma.

hypoxia or ischemia results in the production of oxygen free
radicals and either limits the rate of recovery and/or pro
motes the generation of scar tissue. Systemic and topical
spin-trapping compounds can be used to improve the rate of
healing and decrease scar formation.
Ischemic BoWel Disease
Strangulation of the boWel is a condition that is frequently
fatal in both humans and animals such as dogs, horses and
cattle. Even after resection and anastomosis of the intestine,

considered to be a primary cause. There is no effective
treatment to date.
65

Studies have demonstrated that ischemia induced intesti
nal edema can be prevented or reduced by a number of

different spin-trapping compounds.
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Organs for transplantation are obtained from donors. The
success of the procedure is determined in part by the age
(oxidation) related reduction in organ viability, the amount
of time the organ is in preservation solution, and the status
of the recipient. Previous research has demonstrated that

Endotoxin is a primary factor in the pathophysiology of

equine gastrointestinal disorders and gram negative bacterial
infections. The pathophysiological is similar to that charac

teriZing colitis, salmonellosis, and neonatal septicemia. It is
hypothesized that endotoxin produces its toxic effects by
triggering “oxidative bursts” from sensitiZed macrophages.

spin-trapping compounds can improve the enZymatic status
of the aged brain, restoring enZymatic levels to near those of

These bursts of O2 radicals are intended to kill invading
bacteria associated With the presence of endotoxin.

HoWever, they have the adverse effect of damaging the
tissues in Which they are produced and this tissue damage is
presumably the molecular basis of the pathological changes
associated With endotoxin shock. Spin-trapping compounds
have the ability to trap radicals and alleviate many of the
toxic effects associated With radical formation. Additionally,
recent experiments demonstrate that spin trap molecules
protect rats against endotoxin administration.
Wound and Ulcer Healing
Tissue healing often involves periods of hypoxia or
ischemia as the recovering tissue outgroWs the vascular

supply. Spin-trapping compounds can decrease the damage

the young adult as early as seven days folloWing initiation of
daily treatment With a spin-trapping agent such as PBN.
10

Organ preservation solutions are designed to prepare the
organ to be transplanted for the period of extracorporeal
storage. The most recently developed solution contains
glutathione as an antioxidant. Spin-trapping compounds
differ from glutathione in that they can function both as
antioxidants, trapping oxygen free radicals, as Well as trap

15

ping compounds for both intracellular and extracellular
carbon-centered free radicals.
It is believed organ survival Would therefore be enhanced

by administering spin-trapping compounds to the recipient,
20

as Well as adding the compounds to the organ preservation
solution.

associated With this period of ischemia.

IoniZing Radiation Prophylaxis

Infections as consequence of the development of decubi
tus ulcers is the number one cause of death in the elderly.

environmental toxicant causes its effects by producing

The general clinical impression is that elderly patients are
much more likely to develop these ulcers, compared to

IoniZing radiation as a therapeutic modality and as an

hydroxyl free radicals intracellularly and extracellularly.
25

young adults. Pressure sores develop as a result of the

interruption of blood flow to the skin. This process is
identical to the process of ischemia/reperfusion oxidation of
brain and other tissues. In the geriatric and/or diabetic
patient, pressure sores may develop due to enhanced oxida
tion of the cells of the skin. Based upon the observations that

caused by ischemia/reperfusion injury to tissue. Spin
trapping compounds can be used to selectively treat those
tissues that are not involved by the cancer, thereby increas
30

both as a prophylaxis, applied topically or systemically, as
Well as a post-exposure therapeutic.
35

topically in enhancing recovery.
Reduction in Side-effects of Cancer Chemotherapy
A number of cancer chemotherapeutic agents produce
their cytotoxic effects via the production of oxygen free
radicals Within the cell. The limiting side effects of these

ing the effectiveness of the therapy and decreasing the side
effects of radiation therapies. In the case of environmental

exposures, spin-trapping compounds should be effective

spin-trapping compounds can prevent ischemia/reperfusion
injury to both brain and intestine, it is expected that spin
trapping compounds Will reduce or prevent pressure sores.
In addition, these compounds can be used systemically or

Ultraviolet radiation acts similarly. The cascade that folloWs
is functionally identical to the process of cellular damage

Treatment of Renal Hypertension Disorders, Resulting from
LoW Renal Artery FloW and High Renin
Renal hypertension develops as a result of reduced blood

flow to the kidney. The juxtaglomerular apparatus (JGA)
recogniZes this hypoperfusion and releases renin, Which
results in an angiotensin II mediated increase in blood

compounds are also the result of oxygen free radical pro

pressure (hypertension). Hypoperfusion (hypoxia) is a con
dition that is knoWn to result in signi?cant oxygen free

duction in normal cells. Bleomycin produces pulmonary and

radical production, making it probable that oxygen free

40

cutaneous toxicities as a result of hydroxyl free radical

radicals are likely to be involved in the release of renin by

production. Adriamycin produces cardiac and gastrointesti

the JGA, and therefore manageable at least in part through

nal side-effects. The spin-trapping compound PBN has been
demonstrated to trap the free radicals produced by adriamy

45

cin in heart, brain and other organs of research animals,

Sore muscles as a result of exercise are thought to be a

using the spin-trapping compound PBN. These spin

consequence of free radical mediated peroxidation of skel
etal muscle proteins and lipids. Since chronic treatment With

trapping compounds can be used to limit side effects in
tissues, such as the brain and heart, that are especially

spin-trapping compounds decreases cellular oxidations and
protects enZymes from oxidative inactivation, daily treat

vulnerable to develop free radicals, Without compromising
the therapeutic value of the chemotherapeutic agent.
Skin, Muscle Flap and Organ Survival FolloWing Trans

ment can be used to improve the process of exercise con

ditioning (especially in the horse). Moreover, aged skeletal

plantation
Autologous (self) transplantation of skeletal muscles from

55

one area to another should not involve any immunologic

incompatibilities. HoWever, estimates from one surgeon
suggest that the success rate is more in the area of 50%

success. Acceptance of skin ?ap grafts has an equally loW
success rate. It is postulated that much of the problem arises
as a result of ischemia and reperfusion during the surgical

Well as other organs, during surgery associated With trans

plantation..

muscle is likely to contain constituents, as do most other
cells in the body. Since Work has demonstrated that chronic
administration of the spin-trapping compound PBN can
return cells to the status of a young adult, spin-trapping can
be used to improve the functional status and exercise con

dition of skeletal muscle in aged individuals.
60

Epistaxis (Pulmonary Bleeding in Horses) and Laminitis
Epistaxis (ES) and laminitis are both thought to involve
ischemia/reperfusion injury to the alveolar basement mem

procedures for removal and implantation. FolloWing
ischemia these tissues undergo calcium loading and even
tually necrosis, as in strokes. Spin-trapping compounds can
be used to limit the damage undergone by these tissues, as

administration of spin-trapping compounds.
Exertional Injury to Skeletal Muscle

brane and the lamina propria of the hoof, respectively. Since
both of these conditions involve the process of reperfusion
65

generation of free radicals, spin-trapping compounds can be
used in the prevention, management of treatment of these
conditions.
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Pharmaceutical Compositions
The spin trapping compounds are administered topically,

the active compound to the site of free radical generation.
The spin trapping compound may be administered at once,

locally, or systemically, depending on the application. When

or may be divided into a number of smaller doses to be

administered systemically, the compound is preferably

administered at varying intervals of time. Other methods of
systemic administration can also be used, including inhala
tion or insuf?ation, subcutaneous, intravenous, and intrap
eritoneal administration. The spin trapping compound can

administered orally or intravenously, in an appropriate phar
maceutical carrier such as saline or phosphate buffered

saline (PBS) or in tablet form. For topical application, the
compound is preferably administered in an ointment or
cream base, or by means of a transdermal patch. The

compound can also be administered by controlled delivery
devices, such as biodegradable polymers, or by inhalation,

also be administered topically, in an ointment, creme, or
10

form of a pharmaceutically acceptable salt. As used herein,
the term pharmaceutically acceptable salts or complexes

insuf?ation or nasal spray. Suitable carriers are knoWn to

those skilled in the pharmaceutical area.

refers to salts or complexes of that retain the desired

Effective Dosages of Spin Trapping Compounds
A typical dose of the spin trapping agent for all of the

transdermal patch.
The spin trapping composition can be provided in the

15

above-mentioned conditions is in the range from about 0.1

biological activity of the parent compound and exhibit
minimal, if any, undesired toxicological effects. Nonlimiting

to 100 mg/kg, preferably 0.5 to 50 mg/kg, of body Weight
per day. The effective dosage range of the pharmaceutically

examples of such salts are (a) acid addition salts formed With

acceptable derivatives can be calculated based on the Weight

mic acid, sulfuric acid, phosphoric acid, nitric acid, and the

of the parent spin trapping compound to be delivered. If the
derivative exhibits activity in itself, the effective dosage can

inorganic acids (for example, hydrochloric acid, hydrobro
20

be estimated as above using the Weight of the derivative, or
by other means knoWn to those skilled in the art.

acid, benZoic acid, tannic acid, pamoic acid, alginic acid,

polyglutamic acid, naphthalenesulfonic acids, naphthalene

The compound is conveniently administered in any suit
able unit dosage form, including but not limited to one
containing 5 to 2000 mg, preferably 50 to 1500 mg of active

ingredient per unit dosage form. A oral dosage of 50—1000
mg is usually convenient.
Ideally the active ingredient should be administered to
achieve peak plasma concentrations of the active compound

disulfonic acids, and polygalacturonic acid; (b) base addi
25

calcium, bismuth, barium, magnesium, aluminum, copper,

30

position Will depend on absorption, inactivation, and excre

With an organic cation formed from N,N-dibenZylethylene
diamine, ammonium, or ethylenediamine; or combinations
of (a) and (b); e.g., a Zinc tannate salt or the like.
A preferred mode of administration of the active com
pound is in a form for oral delivery. Oral compositions Will
generally include an inert diluent or an edible carrier.

tion rates of the drug as Well as other factors knoWn to those
35

Preferred pharmaceutical carriers for intravenous adminis
tration are saline or phosphate buffered saline at physiologi

cal pH. Since some compounds are pH sensitive, stability of
the compound in the carrier should be determined and the

speci?c dosage regimens should be adjusted over time
according to the individual need and the professional judg
ment of the person administering or supervising the admin
istration of the compositions, and that the concentration

tion salts formed With polyvalent metal cations such as Zinc,

cobalt, nickel, cadmium, sodium, potassium, and the like, or

of from about 0.5 to 100 mM, preferably about 1 to 30 mM.
The concentration of active compound in the drug com

of skill in the art. It is to be noted that dosage values Will also
vary With the severity of the condition to be alleviated. It is
to be further understood that for any particular subject,

like), and salts formed With organic acids such as acetic acid,
oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic

pH of the carrier adjusted appropriately, or the compound
40

administered in combination With food, a buffering agent, or

in an enteric coating. For oral delivery, the spin trapping
compound may be enclosed in capsules, compressed into

ranges set forth herein are exemplary only and are not
intended to limit the scope or practice of the claimed

tablets, microencapsulated, entrapped in liposomes, in solu

tion or suspension,alone or in combination With a substrate
once, or may be divided into a number of smaller doses to 45 immobiliZing material such as starch or poorly absorbable

composition. The active ingredient may be administered at

salts such as immodium. Pharmaceutically compatible bind
ing agents can be included as part of the composition. The
tablets or capsules may contain, for example, any of the
folloWing ingredients, or compounds of a similar nature: a
binder such as microcrystalline cellulose, gum tragacanth or
gelatin; an excipient such as starch or lactose, a disintegrat
ing agent such as alginic acid, Primogel©, or corn starch; a

be administered at varying intervals of time.

Exemplary dosages of the parent phenyl t-butyl nitrone
administered intravenously range from 0.1 to 10 mg/kg of
body Weight in animals. The effective dosage of PBN in
humans for treating age and ischemic related disorders is
expected to be betWeen approximately 1 and 10 mg/ 70 kg
body Weight. Toxicity tests have demonstrated that PBN is
completely innocuous, With such loW toxicity that it Was not
possible to determine an LDSO. It is possible to extrapolate

from comparative tests using other spin trapping compounds

lubricant such as magnesium stearate or Sterotes; a glidant
such as colloidal silicon dioxide; a sWeetening agent such as
55 sucrose or saccharin;

or a ?avoring agent such as

peppermint, methyl salicylate, or orange ?avoring. When

What the effective dosage for these compounds Will be.
Since the trapping of endogenous free radicals is speci?c
for only those cells that have been exposed to the conditions
that result in the production of free radicals, the traps have

the dosage unit form is a capsule, it can contain, in addition
to material of the above type, a liquid carrier. In addition,
dosage unit forms can contain various other materials Which

little or no effect on normal cells. The bene?cial effects 60

modify the physical form of the dosage unit, for example,

occur only in injured cells, and do not require the presence

coatings of sugar, shellac, or other enteric agents.
Modi?cations and variations of the spin trapping compo

of speci?c receptors, speci?c enZymes, and/or speci?c cell
types.

sitions for the treatment of a variety of disorders associated

Methods of Administration of PBN

The spin trapping compound is preferably administered

65

With oxidation of proteins and/or lipids Will be obvious to
those skilled in the art from the foregoing detailed descrip

systemically, most preferably intravenously or orally, since

tion. Such modi?cations and variations are intended to come

these are the most rapid and ef?cient means for delivering

Within the scope of the appended claims.
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We claim:

or

1. A compound of the formula

H
/

/O'
C=N+

\

X

Y

Where Z is a CL6 straight or branched chain.

wherein:

2. The compound of claim 1, Wherein Y is a tert-butyl

X is imidazolyl, Phenothiazinyl or

10 group that can be hydroXylated or acetylated.

3. The compound of claim 1, Wherein Y is phenyl.
2

@R
\ /

15

4. The compound of claim 1, Wherein Y is
R2

R2=independently (can vary Within the molecule) alkenyl,
n=1_5;
oxyalkenyl’

2O

/O'
—CH=N+\

—C—NHZ> —C—NZ2>

Y

?
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?

?

i

10. The compound of claim 2, Wherein X is phenothiaZi

—NHC——Z, —CZ, —C—OZ, Or —O—C—Z,

_SO3H, _OSO3H, SH,

5. The compound of claim 1, Wherein X is imidaZolyl.
6. The compound of claim 2, Wherein X is imidaZolyl.
7. The compound of claim 3, Wherein X is imidaZolyl.
8. The compound of claim 4, Wherein X is imidaZolyl.
9. The compound of claim 1, Wherein X is phenothiaZinyl.
nyl.

_S(a1ky1), and

111. The compound of claim 3, Wherein X is phenothiaZi
30 ny.

5(a1kenY1)’

12. The compound of claim 4, Wherein X is phenothiaZi

nyl.
A=O or S; and
Z is a C1 to C6 straight, branched, alkyl or cyclic group; 35

13. The compound of claim 1, Wherein X is

and
Y is a tert-butyl group that can be hydroXylated or
acetylated at one or more positions; phenyl or

#452,
\ /
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14. The compound of claims 2, Wherein X is

With the proviso that both X and Y do not simultaneously

represent

50

Wherein n is 1 to 5 and Wherein R2 is —S(alkyl),

15.
16.
17.
18.

The
The
The
The

compound
compound
compound
compound

of claim
of claim
of claim
of claim
*

*

*

1,
2,
3,
4,
*

Wherein
Wherein
Wherein
Wherein
*

Z
Z
Z
Z

is
is
is
is

alkyl.
alkyl.
alkyl.
alkyl.

